Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Market Closed - BME 11:40:02 2024-06-14 am EDT After market 03:59:49 pm
9.188 EUR -0.65% Intraday chart for Grifols, S.A. 9.169 -0.21%
LockThis Alphavalue article, the European leader in independent research, is only available to subscribers .
Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!
Already a customer? Log In
Solaria shares jump on report of takeover interest RE
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
Grifols, S.A. Reports the Successful Closing of the Private Placement of Additional 7.5% Senior Secured Notes Due 2030 CI
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Wednesday Trading MT
Solaria expects energy prices to rise this year RE
Solaria sees higher energy prices later this year, shares rise RE
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Friday Trading MT
GRIFOLS : In line Q1 and on track deleveraging; worth a go Alphavalue
Grifols, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Grifols swings to first-quarter profit, says guidance on track RE
Grifols' CFO Alfredo Arroyo Will Leave Company Next Year RE
GRIFOLS' CFO ALFREDO ARROYO WILL LEAVE COMPANY NEXT Y… RE
Grifols posts first-quarter profit of 21 million euros RE
GRIFOLS CEO SAYS CAN CONFIRM SHANGHAI RAAS TRANSACTION WILL CLO… RE
Transcript : Grifols, S.A., Q1 2024 Earnings Call, May 14, 2024
Spain's Grifols swings to first-quarter profit of 21 mln euros RE
Grifols shares fall after new Gotham City Research report RE
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher MT
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading MT
Chart Grifols, S.A.
More charts
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows: - products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries; - diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers; - hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies; - other (3.1%): primarily intermediate biological products and subcontracted manufacturing services. Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
9.188 EUR
Average target price
17.3 EUR
Spread / Average Target
+88.29%
Consensus
  1. Stock Market
  2. Equities
  3. GRF Stock
  4. News Grifols, S.A.
  5. Grifols : Delivering on a much-needed deleveraging promise